INTELLIA THERAPEUTICS INC
NTLANASDAQ🏆 #1803 by market capEarnings Nov 5US Equity
$799.72▲ $26.95 (+3.37%)
Simulated price1h—
24h▲ 3.4%
7d▲ 7196.7%
14d▲ 7298.0%
30d▲ 6044.6%
1y▲ 7260.5%
🏦Market Cap
$1.68B
Small Cap
📈Revenue Growth (YoY)
+12.6%
Healthy
📊Gross Margin
—
💵FCF Margin
94.8%
Strong
⚖️P/S Ratio
28.4x
Expensive
Otter Score
59
Weak
📊
Analyst Ratings
Price
$799.72
Total
39
Raised
2
Lowered
3
Avg PT
$23.40
H / L
$49 / $9
| Institution | Action | Rating | Date |
|---|---|---|---|
Wolfe Research | Downgraded | Peer Perform → Underperform | 2026-07-16 |
Wedbush | Reiterated | Neutral | 2026-07-10 |
Canaccord Genuity | Reiterated | Buy | 2026-06-16 |
HC Wainwright & Co. | Reiterated | Buy | 2026-06-15 |
Citizens | Reiterated | Market Outperform | 2026-06-15 |
Bernstein | Reiterated | Market Perform | 2026-05-13 |
Goldman Sachs | Reiterated | Sell | 2026-04-28 |
Morgan Stanley | Reiterated | Equal Weight | 2026-04-28 |
Chardan Capital | Reiterated | Buy | 2026-04-27 |
Baird | Reiterated | Neutral | 2026-04-27 |
Jones Trading | Upgraded | Hold → Buy | 2026-03-04 |
RBC Capital | Reiterated | Sector Perform | 2026-03-03 |
Leerink Partners | Reiterated | Outperform | 2026-03-03 |
Wells Fargo | Reiterated | Equal Weight | 2026-03-03 |
Evercore ISI Group | Downgraded | Outperform → In Line | 2025-11-11 |
Truist Securities | Reiterated | Buy | 2025-11-10 |
JP Morgan | Downgraded | Neutral → Underweight | 2025-11-07 |
Barclays | Reiterated | Overweight | 2025-11-07 |
JMP Securities | Reiterated | Market Outperform | 2025-10-28 |
B of A Securities | Reiterated | Buy | 2025-10-27 |
Guggenheim | Reiterated | Buy | 2025-08-13 |
Citigroup | Reiterated | Neutral | 2025-05-09 |
Oppenheimer | Reiterated | Outperform | 2025-01-13 |
BMO Capital | Reiterated | Outperform | 2025-01-10 |
Stifel | Reiterated | Buy | 2024-09-11 |
Cantor Fitzgerald | Reiterated | Overweight | 2024-06-24 |
Raymond James | Reiterated | Outperform | 2023-11-10 |
Credit Suisse | Reiterated | Outperform | 2023-06-13 |
EF Hutton | Reiterated | Buy | 2023-02-24 |
SVB Leerink | Reiterated | Outperform | 2023-01-23 |
Brookline Capital | Upgraded | Hold → Buy | 2022-03-07 |
William Blair | Reiterated | Outperform | 2022-02-18 |
Cowen & Co. | Reiterated | Outperform | 2022-01-31 |
Piper Sandler | Reiterated | Overweight | 2022-01-07 |
Roth Capital | Reiterated | Buy | 2021-06-28 |
BTIG Research | Reiterated | Buy | 2019-02-08 |
Leerink Swann | Reiterated | Outperform | 2018-11-28 |
Jefferies | Reiterated | Buy | 2017-11-01 |
Janney Capital | Reiterated | Buy | 2016-09-29 |
One row per institution, most recent rating